Baron, a neurologist and headache specialist at Cleveland Clinic, explained the significance, clinical data, and patient potential behind CT-132, the first FDA-approved digital therapeutic for migraine prevention.:
Source: Neurology Read More
Eric Baron, DO, on the Approval of CT-132: A Digital Shift in Migraine Care
Related Posts
<![CDATA[FDA AdComm Votes Against Recommending
Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in
AD, Salanersen’s FDA Breakthrough Designation
Meaning]]>
<![CDATA[FDA AdComm Votes Against Recommending Deramiocel Approval, Tazbentetol Shows Durable Cognitive Benefit in AD, Salanersen’s FDA Breakthrough Designation Meaning]]>
